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ABSTRACT 
 Alzheimer’s Disease (AD) is the sixth leading cause of death in the United States with 
no known methods to cure, reverse or halt disease progression. The “metal hypothesis” states 
that CuII, FeIII, ZnII and AlII bind to truncated beta amyloid (Aβ) peptides and form soluble 
oligomers which deposit as senile plaques. These plaques play a crucial role in AD 
pathogenesis. For example, metallated-Aβ aggregates are hypothesized to disrupt membranes 
or generate a reactive oxygen species (ROS) through redox cycling in the presence of CuI/ll or 
FeIII/ll and a reducing agent. ROS can lead to weakened synaptic signaling and neuronal cell 
death. In addition, the ratio of the metal:Aβ can form a variety of metallated-Aβ species which 
are both soluble and neurotoxic. Neurotoxicity can depend on the size of the metallated-Aβ 
species as well as the type of metal present. For example, some studies suggest that CuII ions 
inhibit aggregation and fibrillation reactions induced by ZnII ions and may therefore be 
neuroprotective in this scenario. Regardless to the contradicting roles of metals, the most 
convincing piece of evidence supporting a link between metal homeostasis and the two 
pathological processes (Aβ1-42 aggregation and oxidative damage) comes from chelation 
studies showing solubilization of Aβ1-42 deposits and clinical improvement of patients with 
AD. Studies suggest control of metal imbalances as well as Aβ1-42 concentrations are important 
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“disease-modifying strategies”. Here we will present studies utilizing well-known metal ion 
capture agents, metallodithiolates or NiN2S2 ligands, as chelators to reverse Aβ1-42 
aggregation. Fluorescence anisotropy, UV-Vis spectroscopy, and atomic force microscopy 
studies will show that interactions of Aβ with metal ions are reversible with metallodithiolate 
ligands. These studies will show that metallodithiolates might be a new class of ligands for 
reversing metal-induced Aβ aggregation and a potential disease modifying strategy. 
 
Key Words: mettalodithiolate, metal hypothesis, beta amyloid 
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CHAPTER 1  
INTRODUCTION 
Alzheimer’s Disease (AD) impacts over 5.7 million people in the U.S. each year, costing over 
$225 billion in patient care. AD is characterized by the presence of neurofibrillary tangles 
(NFTs) and senile plaques (SPs) from increased concentrations of amyloid-b-peptide (AB). 
There are many studies that support the amyloid cascade hypothesis and its role in the 
progression of AD(1-4). The hypothesis states that the deposition of misfolded AB leads to 
NFTs, calcium dysregulation, cell death and dementia. The postmortem effects can be 
witnessed from large areas of cell death correlated to the same areas were Aβ is found. Among 
the many species of Aβ, Aβ1-42 has been shown to be the most toxic strain to humans. Reversing 
or slowing the build ups of Aβ1-42 has the potential to slow or reverse AD pathogenesis (  ). In 
vitro, the cascade begins by monomeric Aβ species experiencing changes in pH, temperature 
or interacting with the metal ions in the brain. There are many studies surrounding metal ion 
interactions and the effects they have on aggregation. Aside from their involvement in many 
neurodegenerative diseases, these ions such as Cu2+, Zn2+ and Fe2+ play an important role in 
protecting against free radicals, enabling communication between neurons and helping to 
maintain homeostasis (https://onlinelibrary.wiley.com/doi/10.1002/9781118553480.ch02) .  
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Figure I. Crystallographic structural representation of metallodithiolate forming stable metal 
complexes with Cu, Fe, Ni and Pb (1). 
 In this study the interactions between Aβ, NiN2S2 and metal ions are studied. 
Fluorescence intensity fluorescence anisotropy are used to build a high throughput screening 
assay and study the changes in molecular rotation of Aβ with the addition of metal ions and 
metallodithiolate interactions. UV-Visual Spectroscopy is used to confirm binding interactions 
and Atomic Force Microscopy is utilized to study changes in particle size and shape upon 
interaction.  
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CHAPTER 2  
EXPERIMENTAL SECTION 
Reagents and Buffer Solutions 
Solution of 95% hexafluoroisopropanol (HFIP) is purchased from Sigma Aldrich. 
Beta-amyloid, Aβ1-42 and TAMRA-Aβ1-42 is purchased from Anaspec as lyophilized powders 
and stored at -20°C in HFIP. The Aβ1-42 is modified with a TAMRA dye at the N-terminal end 
of aspartic amino acid residue of the Aβ1-42 sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-
Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-
Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH. 
Aβ Oligomer and Monomer Preparation Sample Preparation for Aβ Binding Studies 
Aβ oligomers are prepared by adding Aβ1-42 (10 µL 222 µM) in HFIP solvent to 90 µL 
in 10 mM HEPES for pH 6.5 or 10 mM PBS. The Aβ1-42 peptide solutions are incubated at 4 
°C for 24 hours to allow for oligomerization. Aβ monomers are prepared by adding Aβ1-42 (10 
µL 222 µM) in HFIP solvent directly to buffered hybrid lipid-coated AuNP solutions. 
 
UV-vis Spectroscopy Studies 
Au-SO-PC-HT and Au-SO-PC-Chol-HTs (1:1) are buffered with 10 µL of 1 M HEPES 
at pH 6.5 or PBS at pH 8.0. Aβ monomers or oligomers are then introduced to the lipid coated 
AuNP solutions to yield final concentrations of 2 μM for monomers or 2 μM for oligomers. 
The UV-vis spectra or DLS is taken before and 15 min after the introduction of Aβ. To probe 
the effect of Aβ on membrane integrity, samples are exposed to cyanide and UV-Vis spectra 
is taken. Cyanide (10 µL 307 mM in H2O) is added to the samples and UV-Vis spectra taken 
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after 1 h of incubation. The final concentration of cyanide in the sample is 3 mM.  UV-vis 
spectra is taken with an Ocean Optics USB4000 UV-vis-NIR spectrophotometer using a 1 cm 
quartz cuvette. Dynamic Light Scattering measurements are recorded with Horiba LB-550 
particle size analyzer with a quartz cuvette.  
 
Fluorescence Anisotropy 
TAMRA-Aβ1-42 (47 nM monomer) is added to 1000 µL 10 mM PBS at pH 8.0 or 10 mM 
HEPES at pH 8.0. The anisotropy of the TAMRA-Aβ1-42 is monitored for 10 min before the 
metal ions (   ) are added to the solution. The sample is incubated for 10 min before the 
anisotropy is recorded for an additional 10 min.  Fluorescence measurements are conducted on 
a PTI spectrophotometer using Felix32 software.  Measurements are taken using a quartz 
cuvette at an excitation of 544 nm, an emission of 580 nm, and a 12 nm bandpass on both 
monochromators.  The steady-state anisotropy (r) is calculated from equation 1: 
𝑟 =  
𝐼𝑉𝑉−𝐺𝐼𝑉𝐻
𝐼𝑉𝑉+2𝐺𝐼𝑉𝐻
                           (1) 
where IVV and IVH are the fluorescence intensities measured, the subscripts indicate the 
orientation of the excitation and emission polarizers, and G = IHV/IHH is the wavelength 
dependent sensitivity of the instrument.16 Reported r values are the average of three 
independent samples each averaged over 10 min.    
 
Atomic Force Microscopy Preparation and Measurements.   
AFM samples were prepared using 10 µL of the 10.25 µM HiLyte-Aβ1-42 stock solution in 
100µL of 10 mM PB pH 8 for a final concentration of .1025 µM HiLyte-Aβ1-42. 5 µL of this 
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solution was deposited dropwise onto freshly cleaved mica. The sample was dried under a 
clean flux of nitrogen gas, rinsed with NANOpure water and again dried under nitrogen. 
Imaging was performed using Digital Instruments Veeco AFM/LFM Instrument (Veeco 
Metrology group). Rotated monolithic, uncoated silicon AFM probes were used with 125 µm 
tip length, 300 kHz resonant frequency and a 40 Newton/meter spring constant model Tap300-
G (Tedpella). Machine was operated in tapping mode keeping drive amplitude to a minimum, 
collecting scans of 2 µm x 2 µm at a slow scan frequency of 1.5-2.5 Hz and 512 x 512 scans 
per line. AFM images were analyzed using Digital Instruments software. Aβ1-42 peptide size 
was determined using the cross section analysis tool and size distribution histogram of each 
image. 
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CHAPTER 3   
 BETA-AMYLOID AND METAL ION BINDING STUDIES 
Figure II i, ii. Representative flouresence Intensity studies of metal chelation via EDTA using 
47 nM TAMRA-Aβ1-42 in 10 mM PBS buffer pH 8.0 after addition of 52 M Cu2+ and 2mM 
EDTA (i). Flouresence intensity measuring interactions in same conditions with Cu2+, Zn2+ 
and Fe2+. 
 A representative fluorescence anisotropy plot of the TAMRA-A1-42 in the absence and 
presence of Cu2+, Zn2+ and Fe2+ is shown in Figure 2 An increase in the anisotropy (r = 
0.1) is observed at 10 min after addition of Au-SO-PC-HT to the TAMRA-A1-42, which 
suggest the hydrodynamic radius is increased and the molecular rotation is slowed, indicating 
binding to the AuNP surface (Figure III.2, (ii)). The beginning of the experiment  (time = 0) 
begins with 47 nM TAMRA-A1-42 in 10 mM PBS buffer pH 8.0, which has an intrinsic 
anisotropy of 0.12 in 10 mM PBS buffer at pH 8. The anisotropy of monomeric TAMRA-A1-
42 alone does not increase over 30 min in the absence of lipid-coated AuNPs. Therefore, the 
observed  in r is due to TAMRA-A1-42 binding to the lipid bilayer of the AuNPs. 
Furthermore, the  in r is indicative of the binding efficiency (% of TAMRA-A1-42  binding 
to the lipid-coated AuNPs) and the relative size of the resulting A-lipid-coated AuNP 
conjugate. This could be because the stronger the affinity A has for the lipid membrane, the 
ii i 
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more monomers that will bind to its surface, and the greater the hydrodynamic radius of the 
TAMRA fluorophore on its surface. 
 
 
 
 
 
 
Figure III. Representative fluorescence anisotropy of 47 nM TAMRA-Aβ1-42 in 10 mM PBS 
buffer pH 8.0 after addition of  52 M Cu2+ and  2 mM EDTA (i). Flouresence anisotropy 
interactions in same conditions with Cu2+, Zn2+ and Fe2+. 
A representative fluorescence anisotropy plot of TAMRA-Aβ1-42 in the absence and 
presence of CuCl2 and EDTA is shown in (Figure III, (i)).  An increase in anisotropy (ravg = 
0.59  0.07) is observed at 10 min after addition of CuCl2 to the TAMRA-Aβ1-42 indicating 
binding (Figure 2, (ii)).  The starting point of the experiment (time = 0) begins immediately 
after metal addition to the TAMRA-Aβ1-42 in 10 mM sodium phosphate buffer pH 8.0.  The 
average intrinsic anisotropy of monomeric TAMRA-Aβ1-42 alone is 0.15  0.03 in 10 mM 
sodium phosphate buffer pH 8.0 over the course of 1 h.  Therefore, the observed  in r of 
TAMRA-Aβ1-42 in the presence of metal ions is not due to self-induced peptide aggregation 
but to the bridging of peptides by the metal ions.  The  in r is a function of binding efficiency 
(% of metals bound to TAMRA-Aβ1-42 and % of TAMRA-Aβ1-42 bound to M
n+-[TAMRA-Aβ1-
42] from bridging interactions) and the relative size of the resulting metallated-conjugate. 
i 
ii 
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Addition of EDTA at 20 min results in a significant drop in r or slow molecular rotation is 
observed. This suggests that the overall hydrodynamic radius has decreased and indicates that 
the peptides are monomeric upon metal capture by EDTA.  The exact size of the aggregate is 
not known and the metal:peptide ratio is not known since excess metal is present in the sample. 
This confirms that metals cause the peptides to aggregate and that aggregation is reversible 
with chelators that have a higher affinity for the metal.   
 
 
Figure IV. Comparison of the change in anisotropy in 10 mM phosphate buffer pH 8.0 of i) 
TAMRA-AB 1-42  ii) after addition of 47 uM of metal ions and iii) after the addition of 5 mM 
NiN2S2. 
To determine if the aggregate was reversible dependent on metal type, anisotropy 
studies were performed in the presence of CuII,  FeIII, and ZnII ions at pH 8.0 (Figure 2).  
The Δr of Hilyte-Aβ1-42 in the presence of CuII is 0.8  ± 0.03 (Figure 2). The average 
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anisotropy in the presence of FeIII and ZnII were Δr = 0.64 ± 0.02 and 0.45 ± 0.05 
respectively. The initial hydrodynamic radius of the CuII species is larger (slower molecular 
rotation) indicating that it has the highest afinity for the AB1-42 peptide. With the addition of 
NiN2S2 there is a 67% decrease in the  hydrodynamic radius of the CuII + AB1-42 aggregate. 
There is a __% increase in the FeIII + AB1-42 aggregate and a __% decrease in the ZnII + 
AB1-42 aggregate. 
These results indicate that the hydrodynamic radius of the FeIII-Aβ1-42 and the ZnII-
Aβ1-42 species is smaller than that of CuII-Aβ1-42, indicating they have a lower affinity for 
TAMRA-Aβ1-42 in comparison to CuII.  Interestingly, in previous studies FeIII hasa higher 
affinity for NiN2S2 than CuII so the result that CuII is aggregation may be reversible and the 
FeIII is not surfaces the question of whether the FeIII-AB1-42 species is experiencing a a 
change in formation.The difference in the hydrodynamic radius between CuII, FeIII, and 
ZnII suggest that the size of the resulting aggregates is likely due to the difference in 
coordination geometry preferences and ligand donor type on the peptide scaffold.  These 
preliminary studies show that at pH 8.0 the change in the hydrodynamic radius is greater for 
CuII > FeIII > ZnII. 
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Evaluating he Effect of NiN2S2 on A interaction with metal ions  
 
 
 
 
 
 
Figure V. UV-Vis spectroscopy comparing change in absorbance of Aβ1-42  with 0.3 µM metal 
ions and 0.4 µM NiN2S2 A) CuSO4 B) ZnBr2 C) FeCl3  
In these UV-Visual studies, a solution of Hilyte-Aβ1-42 in phosphate buffer pH 8, next the metal 
ion was added and traced. Separately the NiN2S2was traced on its own as well as when it was 
added to the Aβ and metal ion solution. The NiN2S2 can be characterized by the bands seen at 
228 and 276 nm. Shown in A, as NiN2S2 is added to the solution of CuSO4 and Aβ, the bands 
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shift to to 244 and 230, representative of a NiN2S2 and Cu
2+complex forming in a 2:4 ratio 
respectively. In B, the peaks shift upwards at the 228 and 276 characteristic bands when NiN2S2 
is added to the AB and Zn2+ complex, showing a rise In C the bands shift to 267 and 297 with 
the addition of NiN2S2
 representing a no interaction between the Zn2+ and the NiN2S2. 
 
 
 
   
  
 
Figure VI. Atomic Force Microscopy 
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CHAPTER 4  
DISCUSSION 
 Figure 5. AFM Analysis of  0.55 µM Aβ1-42 solubilized in HFIP and added to PB pH 
8 incubated at 0 hr with A) AFM image scan of 2 x 2-µm x-y, 5 nm total z-range i) Aβ1-42  ii) 
Aβ1-42  + Cu
II   iii) ) Aβ1-42  + Cu
II  
 + 
 EDTA iv) Aβ1-42  + Zn
II  
 v) Aβ1-42  + Zn
II  
 + 
 EDTA vi) Aβ1-42  
+ Fe
III  
 vii) Aβ1-42  + Fe
III  
 + 
 EDTA. Concentrations of 47 µM of metal ions and 2 mM of 
EDTA were used, added drop wise to a solution B) Histogram distribution analysis of images 
i-vii. To compare the results from the fluorescence anisotropy tests, AFM was used as a 
second assay to study the aggregation effects of pH and metal ions on Aβ1-42.. TAMRA-Aβ1-
42 HFIP solution was used for controlled aggregation studies. Pre-treatment in HFIP allows 
for a homogeneous solution of unaggregated Aβ-peptide for imaging (Figure 5A,i). The z-
height value for individual peptides was ____ (+/- __ ) nm shown in the histogram analysis 
(Figure 5B, i) which agrees with expected size of an Aβ monomer. AFM cannot determine 
molecular weight so it does not provide data to show that the weight of this solution is 
consistent with the Aβ monomer weight of 4 kDa. At pH 8.0 after incubating for 24 hours at 
4º C in phosphate buffer (pH 8) peptide sizes were (____ (+/- __ ) nm proving a __% 
increase in size. After incubation of  Aβ1-42  with CuII for 10 minutes at 25º C there were  
____% and ___% increases in z-height and radius respectively. When exposed to FeIII at pH 
8 the peptide experienced a ____% and ___%. ZnII addition to the peptide resulted in a 
____% and ___% increase in z-height and radius at pH 8. In comparison to the increase in 
hydrodynamic radius observed in the anisotropy studies, the values are consistent for all. The 
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size distribution of aggregated peptides with metal ions is Cu>Fe>Znin pH 8 conditions. 
Next, the addition of EDTA to these peptide-metal ion solutions was studied a second time 
with AFM imaging. Similar reversibility in peptide size can be witnessed with CuII and ZnII. 
A  ____% and ___% decrease in z-height and radius at pH 8. The AFM analysis of EDTA 
addition to the FeIII-Aβ1-42 solution 
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